Discovery of SARS-CoV-2 Nsp14 and Nsp16 Methyltransferase Inhibitors by High-Throughput Virtual Screening

Discovery of SARS-CoV-2 Nsp14 and Nsp16 Methyltransferase Inhibitors by High-Throughput Virtual Screening

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the SARS-CoV-2 mRNA cap methyltransferases (MTases) nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agent...

Full description

Bibliographic Details
Main Authors: Raitis Bobrovs, Iveta Kanepe, Nauris Narvaiss, Liene Patetko, Gints Kalnins, Mihails Sisovs, Anna L. Bula, Solveiga Grinberga, Martins Boroduskis, Anna Ramata-Stunda, Nils Rostoks, Aigars Jirgensons, Kaspars Tars, Kristaps Jaudzems
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Pharmaceuticals
Subjects:
SARS-CoV-2
MTase inhibitors
nsp14
nsp16
antiviral drugs
high-throughput virtual screening
Online Access:https://www.mdpi.com/1424-8247/14/12/1243

Internet

https://www.mdpi.com/1424-8247/14/12/1243

Similar Items